Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.
Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P.
Schmitz-Winnenthal FH, et al. Among authors: schmidt t.
Oncoimmunology. 2015 Mar 16;4(4):e1001217. doi: 10.1080/2162402X.2014.1001217. eCollection 2015 Apr.
Oncoimmunology. 2015.
PMID: 26137397
Free PMC article.